文献速递外周动脉疾病

80岁以上慢性肢体威胁性缺血患者行腹股沟下旁路手术或血管内治疗后的结局

Treatment Outcomes in Octogenarians with Chronic Limb-Threatening Ischemia after Infrainguinal Bypass Surgery or Endovascular Therapy.
PubMed 文献 · Ann Vasc Surg · 2024-05-29

该多中心回顾性研究分析2015至2021年789例腹股沟下血运重建的慢性肢体威胁性缺血(CLTI)患者,比较≥80岁与<80岁患者行旁路手术(BSX)或血管内治疗(EVT)的结局。倾向评分匹配后,两组2年总生存率在BSX和EVT中均以<80岁组更优(P=0.018和P=0.035),但2年保肢率无差异;0-1个危险因素者2年无截肢生存率无差异,而BSX中2-4个危险因素者≥80岁组2年无截肢生存率较差(P=0.015)。

要点

  • 倾向评分匹配后,BSX和EVT组2年总生存率均以<80岁组更优(P=0.018和P=0.035)。
  • BSX和EVT组2年保肢率在≥80岁与<80岁组间均无差异(P=0.621和P=0.287)。
  • BSX中2-4个危险因素者≥80岁组2年无截肢生存率较差(P=0.015)。

核心结论

  • ≥80岁CLTI患者的总生存率低于<80岁患者,但BSX和EVT组保肢率无差异。
  • 尽管年龄≥80岁与较差的总生存相关,0-1个危险因素的患者可能从血运重建(包括BSX)中获益,因为无截肢生存率和Clavien-Dindo≥IV级并发症无差异。

研究设计与样本

  • 多中心回顾性分析,纳入2015至2021年间789例因CLTI行腹股沟下血运重建的患者。
  • 行旁路手术者中≥80岁90例、<80岁200例;行血管内治疗者中≥80岁205例、<80岁294例。

主要发现

  • 倾向评分匹配前多因素分析显示,年龄≥80岁、较低体重指数和血清白蛋白水平、非行走状态及终末期肾病是BSX和EVT组2年死亡的独立危险因素。
  • 倾向评分匹配后,BSX组和EVT组2年总生存率均以<80岁队列更优(P=0.018和P=0.035)。
  • BSX组和EVT组2年保肢率在<80岁与≥80岁队列间均无差异(P=0.621和P=0.287)。
  • 除年龄≥80岁外,0-1个危险因素的BSX和EVT组2年无截肢生存率在<80岁与≥80岁队列间无差异(P=0.957和P=0.655)。
  • BSX中2-4个危险因素者≥80岁队列2年无截肢生存率较差(P=0.015);仅BSX中2-4个危险因素者≥80岁队列Clavien-Dindo≥IV级并发症率趋于更高(P=0.056)。

关键数值与推荐

  • 2年总生存率:BSX组<80岁 vs ≥80岁 P=0.018,EVT组<80岁 vs ≥80岁 P=0.035。
  • 2年保肢率:BSX组<80岁 vs ≥80岁 P=0.621,EVT组<80岁 vs ≥80岁 P=0.287。
  • 2年无截肢生存率(0-1个危险因素):BSX组<80岁 vs ≥80岁 P=0.957,EVT组<80岁 vs ≥80岁 P=0.655。
  • 2年无截肢生存率(BSX中2-4个危险因素):≥80岁队列较差 P=0.015。
  • Clavien-Dindo≥IV级并发症率(BSX中2-4个危险因素):≥80岁队列趋于更高 P=0.056。

临床怎么用

  • 作者认为,0-1个危险因素的≥80岁CLTI患者可能从血运重建(包括BSX)中获益,因无截肢生存率和Clavien-Dindo≥IV级并发症与<80岁患者无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to analyze the clinical outcomes after revascularization for chronic limb-threatening ischemia (CLTI) in patients aged ≥ 80 years and < 80 years. METHODS: We retrospectively analyzed multicenter data of 789 patients who underwent infrainguinal revascularization for CLTI between 2015 and 2021. The end points were 2-year overall survival (OS), amputation-free survival (AFS), limb salvage (LS), and postoperative complications. RESULTS: A total of 90 patients aged ≥ 80 years and 200 patients aged < 80 years underwent bypass surgery (BSX), and 205 patients aged ≥ 80 years and 294 patients aged < 80 years underwent endovascular therapy (EVT). Before the propensity score matching, multivariate analyses showed that age ≥ 80 years, lower body mass index and serum albumin levels, nonambulatory status, and end-stage renal disease were independent risk factors for 2-year mortality in the BSX and EVT groups. After propensity score matching, the 2-year OS was better in the < 80 years cohort than in the ≥ 80 years cohort in both the BSX and EVT groups (P = 0.018 and P = 0.035, respectively). There was no difference in the 2-year LS rates between the < 80 years and the ≥ 80 years cohorts in both the BSX and EVT groups (P = 0.621 and P = 0.287, respectively). According to the number of risk factors, except for age ≥ 80 years, there was no difference in the 2-year AFS rates between the < 80 years and ≥ 80 years cohorts for the BSX and EVT groups with 0-1 risk factor (P = 0.957 and P = 0.655, respectively). However, the 2-year AFS rate was poor, especially in the ≥ 80 years cohort in the BSX with 2-4 risk factors (P = 0.015). The Clavien-Dindo ≥ IV complication rates tended to be higher in the ≥ 80 years cohort than in the < 80 years cohort only in the BSX with 2-4 risk factors (P = 0.056). CONCLUSIONS: Patients with CLTI aged ≥ 80 years had poorer OS than those aged < 80 years. However, there was no difference in LS between the ≥ 80 years and < 80 years cohorts in both the BSX and EVT groups. Although age ≥ 80 years was associated with poorer OS, patients with 0-1 risk factor may benefit from revascularization, including BSX, because no difference was observed in AFS or Clavien-Dindo ≥ IV complications.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Morisaki K, Matsuda D, Guntani A, et al. Treatment Outcomes in Octogenarians with Chronic Limb-Threatening Ischemia after Infrainguinal Bypass Surgery or Endovascular Therapy. Ann Vasc Surg. 2024. PMID: 38821471. doi:10.1016/j.avsg.2024.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。